

# Clinical Oversight Review Board (CORB) Criteria for Prescribing/ Criteria-Based Consultation (CBC) Criteria for Coverage

## Betibeglogene autotemcel (Zynteglo)

### Notes:

- Quantity Limits: Yes (one time dose)
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **Betibeglogene autotemcel (Zynteglo)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

**Initiation (new start) criteria:** Non-formulary **Betibeglogene autotemcel (Zynteglo)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of transfusion dependent beta thalassemia (TDT)
- Must be prescribed by pediatric or adult hematology/oncology specialist
- Patient Must have history of at least 100 ml/kg/year OR 10 units/year of RBC transfusion
- Karnofsky performance status of  $\geq 80\%$  or Lansky performance stats of  $> 80\%$  (if  $< 16$  years old)
- Clinically stable and eligible to undergo hematopoietic stem cell transplant
- Must be reviewed by the Interregional Consultative Physician Panel prior to initiation

**Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously -OR- Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:**

Non-formulary **Betibeglogene autotemcel (Zynteglo)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of transfusion dependent beta thalassemia (TDT)
- Must be prescribed by pediatric or adult hematology/oncology specialist
- Patient Must have history of at least 100 ml/kg/year OR 10 units/year of RBC transfusion
- Karnofsky performance status of  $\geq 80\%$  or Lansky performance stats of  $> 80\%$  (if  $< 16$  years old)
- Clinically stable and eligible to undergo hematopoietic stem cell transplant
- Must be reviewed by the Interregional Consultative Physician Panel prior to initiation